Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys

Experimental Neurology

Volumn 197, Issue 2, 2006, Pages 363-372

  Bankiewicz, Krystof S ^a   Daadi, Marcel ^a   Pivirotto, Philip ^a   Bringas, John ^a   Sanftner, Laura ^b   Cunningham, Janet ^a   Forsayeth, John R ^a   Eberling, Jamie L ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Avigen Inc   (United States)

^c LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

AADC; AAV; Dopamine; Dyskinesias; L dopa; Monkey; MPTP; Parkinson's disease; Striatum

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BENSERAZIDE; CARBIDOPA PLUS LEVODOPA; DOPAMINE; LEVODOPA;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE SEVERITY; DRUG DOSE REGIMEN; DYSKINESIA; FEMALE; FOLLOW UP; HYPERACTIVITY; IMMUNOHISTOCHEMISTRY; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEREOTYPY;

ANIMALS; ANTIPARKINSON AGENTS; AROMATIC-L-AMINO-ACID DECARBOXYLASES; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GENE TRANSFER TECHNIQUES; IMMUNOHISTOCHEMISTRY; LEVODOPA; MACACA MULATTA; MAGNETIC RESONANCE IMAGING; MPTP POISONING; NEURONS; PARKINSON DISEASE, SECONDARY; POSITRON-EMISSION TOMOGRAPHY; TIME FACTORS;

EID: 30444455610     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2005.10.022     Document Type: Article

References (30)

1. G.M. Alexander, D.L. Brainard, S.W. Gordon, M. Hichens, J.R. Grothusen, and R.J. Schwartzman Dopamine receptor changes in untreated and (+)-PHNO-treated MPTP parkinsonian primates Brain Res 547 1991 181 189
2. K.S. Bankiewicz, J.L. Eberling, M. Kohutnicka, W. Jagust, P. Pivirotto, J. Bringas, J. Cunningham, T.F. Budinger, and J. Harvey-White Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach Exp. Neurol. 164 2000 2 14
3. P.J. Bedard, B. Gomez-Mancilla, P. Blanchette, C. Gagnon, P. Falardeau, and T. DiPaolo Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys Adv. Neurol. 60 1993 113 118
4. S. Boyce, C.E. Clarke, R. Luquin, D. Peggs, R.G. Robertson, I.J. Mitchell, M.A. Sambrook, and A.R. Crossman Induction of chorea and dystonia in parkinsonian primates Mov. Disord. 5 1990 3 7
5. L.H. Burns, P. Pakzaban, T.W. Deacon, A.L. Brownell, S.B. Tatter, B.G. Jenkins, and O. Isacson Selective putaminal excitotoxic lesions in non-human primates model the movement disorder of Huntington disease Neuroscience 64 1995 1007 1017
6. T. Chase, T. Engber, and M. Mouradian Striatal dopamine receptive system changes and motor response complications in l-dopa-treated patients with advance disease Adv. Neurol. 60 1993 181 185
7. D. Di Monte, A. McCormack, G. Petzinger, A. Janson, M. Quik, and J. Langston Relationship among nigrostriatal denervation, parkinsonism and dyskinesias in the MPTP primate model Mov. Disord. 15 2000 459 466
8. J.L. Eberling, J. Cunningham, P. Pivirotto, J. Bringas, M.M. Daadi, and K.S. Bankiewicz In vivo PET imaging of gene expression in parkinsonian monkeys Mol. Ther. 8 2003 873 875
9. C.R. Freed, P.E. Greene, R.E. Breeze, W.Y. Tsai, W. DuMouchel, R. Kao, S. Dillon, H. Winfield, S. Culver, J.Q. Trojanowski, D. Eidelberg, and S. Fahn Transplantation of embryonic dopamine neurons for severe Parkinson's disease N. Engl. J. Med. 344 2001 710 719
10. W.C.S.M. Graham, and A.R. Crossman Differential effect of chronic dopaminergic treatment on dopamine D-1 and D-2 receptors in the monkey brain in MPTP-induced parkinsonism Brain Res. 602 1992 290 303
11. J. Hammerstad, W. Woodward, P. Gliessman, B. Boucher, and J. Nutt l-dopa pharmacokinetics in plasma and cisternal and lumbar cerebrospinal fluid of monkeys Ann. Neurol. 27 1990 495 499
12. 18F]fluoro-l-m-tyrosine: metabolism, positron emission tomography kinetics, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lesions in primates Brain Res. 750 1997 264 276
13. J.H. Kordower, and C.E. Sortwell Neuropathology of fetal nigra transplants for Parkinson's disease Prog. Brain Res. 127 2000 333 344
14. Y. Ma, A. Feigin, V. Dhawan, M. Fukuda, Q. Shi, P. Greene, R. Breeze, S. Fahn, C. Freed, and D. Eidelberg Dyskinesia after fetal cell transplantation for parkinsonism: a PET study Ann. Neurol. 52 2002 628 634
15. R. Marconi, D. Lefebvre-Caparros, A.-M. Bonnet, M. Vidailhet, B. Dubois, and Y. Agid Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology Mov. Disord. 9 1994 2 12
16. R.J. Mones, T.S. Elizan, and G.J. Siegel Analysis of l-dopa induced dyskinesias in 51 patients with Parkinsonism J. Neurol., Neurosurg. Psychiatry 34 1971 668 673
17. M.M. Mouradian, J.L. Juncos, G. Fabbrini, and T.N. Chase Motor fluctuations in Parkinson's disease: pathogenic and therapeutic studies Ann. Neurol. 22 1987 475 479
18. J. Nutt Dyskinesia induced by levodopa and dopamine agonists in patients with Parkinson's disease A. Lang W. Weiner Drug-Induced Movement Disorders 1992 Futura Mount Kisko 281 314
19. J.A. Obeso, C.W. Olanow, and J.G. Nutt Levodopa motor complications in Parkinson's disease Trends Neurosci, 23 2000 S2 S7
20. J.A. Obeso, M.C. Rodriguez-Oroz, M. Rodriguez, J.L. Lanciego, J. Artieda, N. Gonzalo, and C.W. Olanow Pathophysiology of the basal ganglia in Parkinson's disease Trends Neurosci. 23 2000 S8 S19
21. C.W. Olanow, and J.A. Obeso Preventing levodopa-induced dyskinesias Ann. Neurol. 47 2000 S167 S176 (discussion S176-168)
22. C.W. Olanow, T. Freeman, and J. Kordower Transplantation of embryonic dopamine neurons for severe Parkinson's disease N. Engl. J. Med. 345 2001 146 (author reply 147)
23. C.W. Olanow, C.G. Goetz, J.H. Kordower, A.J. Stoessl, V. Sossi, M.F. Brin, K.M. Shannon, G.M. Nauert, D.P. Perl, J. Godbold, and T.B. Freeman A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease Ann. Neurol. 54 2003 403 414
24. A. Peppe, J. Dambrosia, and T. Chase Risk factor for motor response complications in l-dopa-treated Parkinsonian patients Adv. Neurol. 60 1993 698 702
25. R. Sanchez-Pernaute, J. Harvey-White, J. Cunningham, and K.S. Bankiewicz Functional effect of adeno-associated virus mediated gene transfer of aromatic l-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats Mol. Ther. 4 2001 324 330
26. J. Schneider Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage Pharmacol. Biochem. Behav. 34 1989 193 196
27. J.S. Schneider, H. Gonczi, and E. Decamp Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms Brain Res. 990 2003 38 44
28. K. Steece-Collier, T.J. Collier, P.D. Danielson, R. Kurlan, D.M. Yurek, and J.R. Sladek Jr. Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in parkinsonian rats Mov. Disord. 18 2003 1442 1454
29. J. Walters, D. Bergstrom, J. Carlson, and T. Chase D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects Science 236 1987 719 722
30. T. Zimmerman, J. Sage, A. Lang, and M. Mark Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment Mov. Disord. 9 1994 173 177